CNCR Loncar Cancer Immunotherapy ETF
The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.
No price history on file.
Performance
| 1M | 3M | YTD | 1Y | 3Y ann. | 5Y ann. | |
|---|---|---|---|---|---|---|
| CNCR | 0.0% | 0.0% | 0.0% | 0.0% | -4.7% | -21.4% |
| Equity average (4625 funds) | -2.1% | +2.7% | +87.6% | +61193.5% | +13.9% | +2.3% |
Insider activity in the holdings
Open-market insider buying across this fund’s holdings over 90 days, weighted by holding weight: +$32K net.
| Holding | Weight | Insiders bought | Insiders sold |
|---|---|---|---|
| ATRA Atara Biotherapeutics, Inc. | 3.30% | $1000K | $41K |
Holdings · as of Apr 17, 2023
| # | Holding | Weight |
|---|---|---|
| 1 | TIL Instil Bio, Inc. | 3.59% |
| 2 | REPL Replimune Group, Inc. | 3.54% |
| 3 | IOVA Iovance Biotherapeutics, Inc. | 3.47% |
| 4 | ZYME Zymeworks Inc. | 3.45% |
| 5 | GMAB Genmab A/S | 3.42% |
| 6 | ARGX argenx SE | 3.42% |
| 7 | CRSP CRISPR Therapeutics AG | 3.39% |
| 8 | BMY Bristol-Myers Squibb Company | 3.39% |
| 9 | AZN AstraZeneca PLC | 3.39% |
| 10 | MRK Merck & Co., Inc. | 3.37% |
| 11 | XNCR Xencor, Inc. | 3.37% |
| 12 | NKTR Nektar Therapeutics | 3.37% |
| 13 | REGN Regeneron Pharmaceuticals, Inc. | 3.36% |
| 14 | FATE Fate Therapeutics, Inc. | 3.33% |
| 15 | GILD Gilead Sciences, Inc. | 3.33% |
| 16 | RCUS Arcus Biosciences, Inc. | 3.32% |
| 17 | ATRA Atara Biotherapeutics, Inc. | 3.30% |
| 18 | ALLO Allogene Therapeutics, Inc. | 3.29% |
| 19 | RUBY Rubius Therapeutics, Inc. | 3.29% |
| 20 | TRIL Trillium Therapeutics Inc. | 3.29% |
| 21 | BLUE bluebird bio, Inc. | 3.28% |
| 22 | IBRX ImmunityBio, Inc. | 3.28% |
| 23 | IMAB I-Mab | 3.25% |
| 24 | STTK Shattuck Labs, Inc. | 3.23% |
| 25 | IGMS IGM Biosciences, Inc. | 3.23% |
| 26 | ALXO ALX Oncology Holdings Inc. | 3.21% |
| 27 | LEGN Legend Biotech Corporation | 3.20% |
| 28 | BGNE BeiGene, Ltd. | 3.19% |
| 29 | MGNX MacroGenics, Inc. | 3.17% |
| 30 | YMAB Y-mAbs Therapeutics, Inc. | 3.12% |
| 31 | CASH&OTHER | 0.13% |
Sector breakdown
Not on file.
Country breakdown
Not on file.
Distributions
| Date | Per unit |
|---|---|
| Dec 29, 2021 | $1.8533 |
| Dec 30, 2020 | $0.2881 |
| Dec 28, 2017 | $0.3502 |
| Dec 29, 2015 | $0.1060 |
Members of Congress who disclosed this ETF
No member of Congress has disclosed a trade in CNCR in the filings we hold.
Fund facts, prices, performance and distributions: our market-data vendor. Holdings: the vendor and SEC Form N-PORT. Insider and Congress data: InsiderBuying. Last updated Nov 13, 2026. This is historical data, not investment advice. Report a data error